Could Lilly’s donanemab readout in Alzheimer’s boost Biogen’s prospects?

Could Lilly’s donanemab readout in Alzheimer’s boost Biogen’s prospects?

Source: 
Pharmaforum
snippet: 

When Eli Lilly reported results for donanemab in Alzheimer’s disease earlier this week it was hailed as a rare win for the amyloid hypothesis, although there’s no shortage of candidates that have failed despite positive mid-stage trial results.